Evidence map›Paper›PMID 39720522›Full record

ArticleiScience2024

Peroxiredoxin 1-Toll-like receptor 4-p65 axis inhibits receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation.

Jisu Park, Sanggil Kim, Hye-Yeon Jung, Eun Hwan Bae, Minhye Shin, Jae-Il Park, So-Young Choi, Sun-Ju Yi, Kyunghwan Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jisu ParkDepartment of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Sanggil KimDepartment of Lead Optimization, New Drug Development Center, Osong Medical Innovation Foundation (KBio), 123 Osongsaengmyeng-ro, Cheongju, Chungbuk, Republic of Korea.
Hye-Yeon JungKorea Basic Science Institute, Gwangju Center at Chonnam National University, Gwangju, Republic of Korea.
Eun Hwan BaeDepartment of Microbiology, College of Medicine, Inha University, Incheon, Republic of Korea.
Minhye ShinDepartment of Microbiology, College of Medicine, Inha University, Incheon, Republic of Korea.
Jae-Il ParkKorea Basic Science Institute, Gwangju Center at Chonnam National University, Gwangju, Republic of Korea.
So-Young ChoiDepartment of Lead Optimization, New Drug Development Center, Osong Medical Innovation Foundation (KBio), 123 Osongsaengmyeng-ro, Cheongju, Chungbuk, Republic of Korea.
Sun-Ju YiDepartment of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Kyunghwan KimDepartment of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peroxiredoxin 1 (PRDX1), an intracellular antioxidant enzyme, has emerged as a regulator of inflammatory responses via Toll-like receptor 4 (TLR4) signaling. Despite this, the mechanistic details of the PRDX1-TLR4 axis and its impact on osteoclast differentiation remain elusive. Here, we show that PRDX1 suppresses RANKL-induced osteoclast differentiation. Utilizing pharmacological inhibitors, we reveal that PRDX1 inhibits osteoclastogenesis through both TLR4/TRIF and TLR4/MyD88 pathways. Transcriptome analysis revealed PRDX1-mediated alterations in gene expression, particularly upregulating serum amyloid A3 (

Indexed as

Cellular physiologyMolecular biologyTranscriptomics

Identifiers

PMID39720522
PMCPMC11667055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.